LOL quote, "yes, things have been stagnant in the past, and i feel your frustration captain, however...OCAT just signed licensing deal with ALLELE for IPSC technology. I believe this is a big step forward for company in non core programs like platelets. OCAT is also much farther in current trials. They have 2 published papers and moving into phase 2 "PIVOTAL" trials shortly. "
Uh, no- not exactly.
1) They signed an "agreement" with no details given that it's even a "license" or if it's exclusive or for how long or for how much money, etc. NOTHING of detail was given in that vague PR. Nowhere did it say conclusively that they, OCAT now "hold license" to said technology.
2) "2 published papers" LOL. OK. ANY MONEY for those papers- like $10's of MILLIONS in cold hard cash that OCAT needs to even get out of the starting blocks on a large, Phase II, FDA quality trial? They can publish "papers" till the cows come how- who cares? If there's no money it's all moot and for nothing. A Lincoln finance "credit card" doesn't fund any trials- thus their "big trials" are in the parking space going nowhere as of right this moment. Simple as that.
3) Their own Sr. mgt stated they are focusing on "core programs" as they're going to be lucky to "fund what they have" on their plate with the "eye stuff" - not "platelets" or whatever. What money that they do not have is going to fund the other "stuff" when they can't even get their key, most important trial(s) off the dime and moving ahead- the one they said they "hope to have advancing in late 2014" and how we're going to hit APRIL 2015 and guess where that trials gone? NOWHERE. They missed another milestone target and ole "PR" bait n switch IMO. 4 months into the yr 2015 and the "by late 2014" trial is going nowhere fast. Same old ACTC/OCAT broken record bad tune IMO.
All there is right now is a bunch of vague speculations and years, years to even a shot at a commercial product, let alone sales, etc. Meanwhile- unless they pull a magic rabbit out of some hat, DILUTION is their only means forward, and lots of it. They didn't file that $100 million shelf offering for no reason- and have it sitting open for no reason. They're gonna spend money and shares by the super-tanker full IMO. It's all they got right now. Lincoln is survival money at this point- it's not "progress forward" money. At this point- they have no "progress forward" money and until they reveal where and how that's going to happen- it's dead money in here IMO. If the "go forward" money turns out to be highly dilutive- like another go at a low priced secondary- then there's a high probability of big downside still in the present, already stagnant share price.
That's the reality version versus the fantasy version IMO. "hope" doesn't make business- CASH makes businesses and OCAT is cash poor right now for the business/field they want to play in. No cash, and I don't care if they write and publish 100 more "papers"- it'll make no difference. Their first "paper" obviously went over like a lead brick- they couldn't even price and pull off a decent, $60 mil secondary based on that "paper" - no "big takers" thought the "paper" was worth the coin apparently, and that was with 3 large, expensive underwriters trying to pitch and sell the deal. You think that was for free? OCAT just sunk a pile of lost money on that blown secondary- more dilution coin down the proverbial rat hole to nowhere. Par for their course IMO. Just add it to the "legal SEC payoff" and all the other money down the rat hole- heck, it's only dilution shares, what's another $million lost or whatever.
